Next Article in Journal
The Expanding Role of MT1-MMP in Cancer Progression
Next Article in Special Issue
Novel 11-Substituted Ellipticines as Potent Anticancer Agents with Divergent Activity against Cancer Cells
Previous Article in Journal
Iron Supplementation Therapy, A Friend and Foe of Mycobacterial Infections?
Previous Article in Special Issue
3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells
Article Menu

Export Article

Open AccessArticle

Magnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin: A Perspective for Glioblastoma Treatment

1
Leibniz Institute of Solid State and Material Research Dresden, 01069 Dresden, Germany
2
College of Pharmacy and Medical Sciences, Hebron University, Hebron 00970, Palestine
3
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS), 87036 Rende, Italy
4
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2031, Australia
5
ARC Centre of Excellence for Convergent BioNano Science and Technology, Australian Centre for NanoMedicine, UNSW Sydney, Sydney 2052, Australia
6
School of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney, Sydney 2052, Australia
7
Department of Physics, University of Texas at El Paso, El Paso, TX 79968, USA
8
Institute of Nanoscience of Aragon (INA) & Department of Condensed Matter Physics, University of Zaragoza, 50018 Zaragoza, Spain
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(2), 76; https://doi.org/10.3390/ph12020076
Received: 15 April 2019 / Revised: 10 May 2019 / Accepted: 16 May 2019 / Published: 18 May 2019
(This article belongs to the Special Issue Anticancer Drugs)
  |  
PDF [7162 KB, uploaded 18 May 2019]
  |  

Abstract

Selective vectorization of Cisplatin (CisPt) to Glioblastoma U87 cells was exploited by the fabrication of a hybrid nanocarrier composed of magnetic γ-Fe2O3 nanoparticles and nanographene oxide (NGO). The magnetic component, obtained by annealing magnetite Fe3O4 and characterized by XRD measurements, was combined with NGO sheets prepared via a modified Hummer’s method. The morphological and thermogravimetric analysis proved the effective binding of γ-Fe2O3 nanoparticles onto NGO layers. The magnetization measured under magnetic fields up to 7 Tesla at room temperature revealed superparamagnetic-like behavior with a maximum value of MS = 15 emu/g and coercivity HC ≈ 0 Oe within experimental error. The nanohybrid was found to possess high affinity towards CisPt, and a rather slow fractional release profile of 80% after 250 h. Negligible toxicity was observed for empty nanoparticles, while the retainment of CisPt anticancer activity upon loading into the carrier was observed, together with the possibility to spatially control the drug delivery at a target site. View Full-Text
Keywords: magnetic targeting; graphene oxide; maghemite; glioblastoma; cisplatin magnetic targeting; graphene oxide; maghemite; glioblastoma; cisplatin
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Makharza, S.A.; Cirillo, G.; Vittorio, O.; Valli, E.; Voli, F.; Farfalla, A.; Curcio, M.; Iemma, F.; Nicoletta, F.P.; El-Gendy, A.A.; Goya, G.F.; Hampel, S. Magnetic Graphene Oxide Nanocarrier for Targeted Delivery of Cisplatin: A Perspective for Glioblastoma Treatment. Pharmaceuticals 2019, 12, 76.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top